Tiger-1 is a double-blind, placebo-controlled, randomized study comparing 60mg of Denufosol to placebo, administered three times daily by jet nebulizer, in approximately 350 patients with mild cystic fibrosis
Zybrestat, delivered in combination with Avastin, appeared safe and well-tolerated and resulted in significantly enhanced tumor blood-flow reductions as measured by DCE-MRI imaging, and demonstrated early evidence of
In the study measuring LDL-cholesterol reduction, patients treated with a combination of 10mg of Merck & Co. and Schering-Plough’s Zetia (ezetimibe) and 10mg AEGR-733, experienced LDL-C reductions of
EpiCept successfully identified the maximum tolerated dose of EPC2407 in the Phase I study. The maximum tolerated dose was well below the dose which produced the expected toxicity
The portfolio includes the dermatology products, Solaraze (3% gel diclofenac sodium) and Vaniqa (eflornithine hydrochloride), and six other non-promoted products across a range of indications, which are principally
The patent covers the formulation of pain drug Opana ER (oxymorphone HCl) extended-release tablets CII using Penwest’s TIMERx technology and is exclusively licensed to Endo Pharmaceuticals pursuant to
Having received approval, market launch is expected in the first quarter of 2008. Earlier, Dusa entered into an exclusive marketing, distribution and supply agreement with Daewoong Pharmaceutical and
The new Phase II open label study at McGill University will explore the effect of an investigational drug on patients with recurrent or advanced cancer. Researchers indicate that
The primary focus of the project will be to develop a 5 Lipoxygenase (5-LO) genotyping panel for VIA-2291, VIA’s lead candidate for cardiovascular disease, as well as a
NicOx and Ferrer initiated their development program focused on high potency, nitric oxide-donating anti-inflammatory agents, for the treatment of a range of skin disorders. Ennio Ongini, vice president
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.